GLP-1 class safety monitoring should include awareness of these important risks: Pancreatitis : Patients should promptly report severe abdominal pain, with or without vomiting Gallbladder disease : Report symptoms of biliary colic or cholecystitis Acute kidney injury : Maintain adequate hydration, especially if experiencing nausea/vomiting Hypoglycemia : Increased risk when used with insulin or sulfonylureas Suicidal ideation : For patients using Wegovy or Zepbound, monitor for mood changes Patients should be counseled to report any neck swelling, difficulty swallowing, persistent hoarseness, or palpable thyroid nodules, as these warrant evaluation regardless of GLP-1 use
However, if you are experiencing significant nausea from your weight loss medication, you should prioritize foods that are easy to digest
Retatrutide se investiga como triagonista de GIP, GLP-1 y glucagn
Yes, but caution is advised
Long-term effect of weight regain following behavioral weight management programs on cardiometabolic disease incidence and risk: systematic review and meta-analysis
People with obesity are often marginalized, says Vij